CN110124042A - The composition of inhibition underarm odor without aluminium - Google Patents
The composition of inhibition underarm odor without aluminium Download PDFInfo
- Publication number
- CN110124042A CN110124042A CN201910448380.8A CN201910448380A CN110124042A CN 110124042 A CN110124042 A CN 110124042A CN 201910448380 A CN201910448380 A CN 201910448380A CN 110124042 A CN110124042 A CN 110124042A
- Authority
- CN
- China
- Prior art keywords
- zinc
- acid
- composition
- aluminium
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 229910052782 aluminium Inorganic materials 0.000 title claims abstract description 20
- 239000004411 aluminium Substances 0.000 title claims abstract description 20
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 230000005764 inhibitory process Effects 0.000 title claims abstract description 17
- 150000003751 zinc Chemical class 0.000 claims abstract description 23
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 claims abstract description 20
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000002243 precursor Substances 0.000 claims abstract description 18
- 230000010181 polygamy Effects 0.000 claims abstract description 9
- 239000000178 monomer Substances 0.000 claims abstract description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 58
- 108010052500 Calgranulin A Proteins 0.000 claims description 43
- 239000011701 zinc Substances 0.000 claims description 29
- 229910052725 zinc Inorganic materials 0.000 claims description 29
- -1 lysine-zn Chemical compound 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 12
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 12
- 229960003720 enoxolone Drugs 0.000 claims description 12
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 10
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 10
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 10
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 10
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 claims description 10
- 229940011658 asiatic acid Drugs 0.000 claims description 10
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 claims description 10
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 claims description 10
- 229940100243 oleanolic acid Drugs 0.000 claims description 10
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 10
- 229940096998 ursolic acid Drugs 0.000 claims description 10
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 10
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 claims description 9
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 claims description 9
- 230000001166 anti-perspirative effect Effects 0.000 claims description 9
- 239000003213 antiperspirant Substances 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 9
- 229940001447 lactate Drugs 0.000 claims description 9
- 239000004530 micro-emulsion Substances 0.000 claims description 9
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 8
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 6
- 241001092040 Crataegus Species 0.000 claims description 6
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- 239000012752 auxiliary agent Substances 0.000 claims description 6
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 6
- 229940110280 zinc methionine Drugs 0.000 claims description 6
- CNMFGFBWPBBGKX-SCGRZTRASA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate Chemical compound [Zn+2].CSCC[C@H](N)C([O-])=O.CSCC[C@H](N)C([O-])=O CNMFGFBWPBBGKX-SCGRZTRASA-L 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- 238000013329 compounding Methods 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000837 restrainer Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- 229960001763 zinc sulfate Drugs 0.000 claims description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 5
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000002615 epidermis Anatomy 0.000 claims description 4
- 208000002557 hidradenitis Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 235000011478 zinc gluconate Nutrition 0.000 claims description 4
- BGMYHTUCJVZIRP-UHFFFAOYSA-N Nojirimycin Natural products OCC1NC(O)C(O)C(O)C1O BGMYHTUCJVZIRP-UHFFFAOYSA-N 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- BGMYHTUCJVZIRP-GASJEMHNSA-N nojirimycin Chemical compound OC[C@H]1NC(O)[C@H](O)[C@@H](O)[C@@H]1O BGMYHTUCJVZIRP-GASJEMHNSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- MFQVERMEVJFAMB-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;zinc Chemical compound [Zn].OC(=O)[C@@H](N)CC1=CC=CC=C1 MFQVERMEVJFAMB-QRPNPIFTSA-N 0.000 claims description 2
- LQZFQLVBZRVDLJ-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;zinc Chemical compound [Zn].OC(=O)[C@@H](N)CC(O)=O LQZFQLVBZRVDLJ-DKWTVANSSA-N 0.000 claims description 2
- HCFJVKDUASLENU-WCCKRBBISA-N (2s)-pyrrolidine-2-carboxylic acid;zinc Chemical compound [Zn].OC(=O)[C@@H]1CCCN1 HCFJVKDUASLENU-WCCKRBBISA-N 0.000 claims description 2
- NEVHPNCTUPGPLY-FHAQVOQBSA-N (2s,3s)-2-amino-3-methylpentanoic acid;zinc Chemical compound [Zn].CC[C@H](C)[C@H](N)C(O)=O NEVHPNCTUPGPLY-FHAQVOQBSA-N 0.000 claims description 2
- XJYXFGBRNDJLPC-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;zinc Chemical compound [Zn].OC(=O)C(O)C(O)C(O)=O XJYXFGBRNDJLPC-UHFFFAOYSA-N 0.000 claims description 2
- CLWNPUARORRDFD-UHFFFAOYSA-N 2-hydroxybutanedioic acid;zinc Chemical compound [Zn].OC(=O)C(O)CC(O)=O CLWNPUARORRDFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 238000006298 dechlorination reaction Methods 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001110 miglitol Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- TVOIPJPTFTYKQM-UHFFFAOYSA-N propanedioic acid;zinc Chemical compound [Zn].OC(=O)CC(O)=O TVOIPJPTFTYKQM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 229960001939 zinc chloride Drugs 0.000 claims description 2
- 239000011746 zinc citrate Substances 0.000 claims description 2
- 235000006076 zinc citrate Nutrition 0.000 claims description 2
- 229940068475 zinc citrate Drugs 0.000 claims description 2
- 239000011576 zinc lactate Substances 0.000 claims description 2
- 235000000193 zinc lactate Nutrition 0.000 claims description 2
- 229940050168 zinc lactate Drugs 0.000 claims description 2
- FHIDHDJKGHORIB-CEOVSRFSSA-L zinc;(2r)-2-amino-3-sulfanylpropanoate Chemical compound [Zn+2].SC[C@H](N)C([O-])=O.SC[C@H](N)C([O-])=O FHIDHDJKGHORIB-CEOVSRFSSA-L 0.000 claims description 2
- GAMIYQSIKAOVTG-UHFFFAOYSA-L zinc;2-aminopentanedioate Chemical compound [Zn+2].[O-]C(=O)C(N)CCC([O-])=O GAMIYQSIKAOVTG-UHFFFAOYSA-L 0.000 claims description 2
- ZNVKGUVDRSSWHV-UHFFFAOYSA-L zinc;4-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 ZNVKGUVDRSSWHV-UHFFFAOYSA-L 0.000 claims description 2
- ZPEJZWGMHAKWNL-UHFFFAOYSA-L zinc;oxalate Chemical compound [Zn+2].[O-]C(=O)C([O-])=O ZPEJZWGMHAKWNL-UHFFFAOYSA-L 0.000 claims description 2
- 102100024645 ATP-binding cassette sub-family C member 8 Human genes 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 1
- 229960000314 zinc acetate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 206010040904 Skin odour abnormal Diseases 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 241000894006 Bacteria Species 0.000 abstract description 8
- 210000004907 gland Anatomy 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 210000004243 sweat Anatomy 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 229910052573 porcelain Inorganic materials 0.000 abstract 1
- 102000018803 Calgranulin A Human genes 0.000 description 40
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 31
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 16
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 229960000485 methotrexate Drugs 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 229930003427 Vitamin E Natural products 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 239000011709 vitamin E Substances 0.000 description 8
- 235000019165 vitamin E Nutrition 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- 102100037129 ATP-binding cassette sub-family C member 11 Human genes 0.000 description 7
- 101001029057 Homo sapiens ATP-binding cassette sub-family C member 11 Proteins 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000003787 Anoctamin-1 Human genes 0.000 description 6
- 108090000160 Anoctamin-1 Proteins 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000036773 apocrine secretion Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000004519 grease Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000000106 sweat gland Anatomy 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010051820 Sordes Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000186245 Corynebacterium xerosis Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- RGRNSTGIHROKJB-UHFFFAOYSA-N 3-hydroxy-3-methylhexanoic acid Chemical compound CCCC(C)(O)CC(O)=O RGRNSTGIHROKJB-UHFFFAOYSA-N 0.000 description 2
- 101150110927 ABCC11 gene Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical group Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000004064 cosurfactant Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
- 229960002064 kanamycin sulfate Drugs 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229940051841 polyoxyethylene ether Drugs 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940083957 1,2-butanediol Drugs 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- ZITBHNVGLSVXEF-UHFFFAOYSA-N 2-[2-(16-methylheptadecoxy)ethoxy]ethanol Chemical compound CC(C)CCCCCCCCCCCCCCCOCCOCCO ZITBHNVGLSVXEF-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001337814 Erysiphe glycines Species 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WWYHAQDAMPXWSI-UHFFFAOYSA-N dodecan-1-ol;methane Chemical compound C.CCCCCCCCCCCCO WWYHAQDAMPXWSI-UHFFFAOYSA-N 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229960005082 etohexadiol Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940113096 isoceteth 20 Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YJBSVLMGKHFEAY-UHFFFAOYSA-N methyl decanoate;methyl octanoate Chemical compound CCCCCCCC(=O)OC.CCCCCCCCCC(=O)OC YJBSVLMGKHFEAY-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WIBFFTLQMKKBLZ-SEYXRHQNSA-N n-butyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCC WIBFFTLQMKKBLZ-SEYXRHQNSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- MKSVFGKWZLUTTO-FZFAUISWSA-N puromycin dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO MKSVFGKWZLUTTO-FZFAUISWSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220056641 rs730880953 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- RCVXUZDXWKYWDH-UHFFFAOYSA-N tetradecyl 2,3-dihydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(O)CO RCVXUZDXWKYWDH-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 239000012855 volatile organic compound Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Abstract
A kind of composition of the inhibition underarm odor without aluminium, using pentacyclic triterpenoid monomer or monomer composition 0.01%-5%, soluble single aglucon or polygamy base zinc salt 0.5%-10%, 1-DNJ or derivatives thereof 0-5.0% is main active, by inhibiting the transhipment of body odour object precursor, killing to play the role of bacterium, the inhibition armpit top gland sweat secretion of decomposition to body odour object precursor, achieve the purpose that inhibit underarm odor.The features such as the composition is no aluminium porcelain enamelling, and clear with component, mechanism is clear, and safety is used for a long time, rapid-action, and effect is good, and lasting.
Description
Technical field
The invention belongs to biomedicine field, be related to the compositions such as pentacyclic triterpenoid and zinc salt preparation underarm odor control
Treat the purposes in drug.
Background technique
The smell is awful for underarm odor, pollutes clothes, is painful and trouble a problem.Certain people are to offending smell
Frightened, detest or psychological allergy are shown, some people's smell neurosis are even resulted in.Underarm odor seriously affects work, life and society
It hands over.In Japan, underarm odor is considered as a kind of disease, is the project of national health insurance.Underarm odor crowd is in the Asians such as China
About 20%.
Currently, anti-underarm odor drug on the market is mostly antiperspirant, by inhibiting the apocrine sweat gland of oxter to perspire, inhibit underarm odor
Generate, wherein main antiperspirant is aluminium chloride or basic zirconium chloride aluminium, the shortcomings that these antiperspirants is: 1) mechanism is not
It is bright；2) aluminium may influence nervous system, and there are uncertain safeties；3) there are the side effects such as skin darkening or allergy.Due to aluminium
Safety uncertainty, therefore, exploitation is free of the osmidrosis treatment drug of aluminium, is the master of current osmidrosis treatment pharmaceutical preparation research and development
Want direction.
Summary of the invention
It is needed in view of the shortcomings of the prior art with market, the inhibition underarm odor without aluminium that the purpose of the present invention is to provide a kind of
Composition.It is intended to overcome the uncertainty of the safety of aluminium.
The present invention starts with from the following aspects, and 1) inhibit axillary apocrine to perspire, quantity of perspiration is reduced, i.e. reduction sordes matter
The secretory volume of precursor；2) activity for inhibiting MRP8 reduces body odour object precursor to external transhipment；It reduces in sweat before sordes matter
The amount of body；3) bacterium that can decompose smelly precursors is killed.
Inhibition perspires, and reduces the amount of oxter body odor substance, can play a part of to inhibit underarm odor.It perspires in vivo complicated by one
Mechanism control.Studies have shown that calcium ion activated chloride channel CFTR (L é rias, Pinto et al., Cellular
Signalling, 2018,10-19) and TMEM16A (Wilson and Metzler-Wilson, Experimental
Dermatology, 2015,177-178) it plays an important role in the forming process of primary sweat.TMEM16A is in apocrine secretion
It is expressed in liquid gland, ephidrosis is related with the transcripton of the gene in apocrine secretion liquid gland shearing diversity.Theoretically, inhibit
TMEM16A may perspire inhibition and play an important role.
Human scent is a kind of mixture (Takeuchi, the Yabuki et of complicated volatile organic matter (VOCs)
al., Flavour & Fragrance Journal, 2013, 223–230).Underarm odor be by C2-C11 just, branch and not
The complex mixture of unsaturated organic acid composition, main component is euro -3- methyl -2- hexenoic acid (E-3M2H), 3- hydroxyl -3-
Methylhexanoic acid (3H3M), 3- hydroxy-3-methyl caproic acid (HMHA) and volatile sulfur compounds, especially 3- methyl -3-
Sulphur -1- alcohol (3M3SH) (Martin, Saathoff et al., Journal of Investigative
Dermatology, 2010,529-540), this sulfur-containing compound is typically found in very low level, but is had very high
Odor impact power (i.e. low odor threshold).Volatilize sex steroid, such as 5 α-androgen -16- alkene -3- ketone (androsterone) and 5 α-hero
- 3 β -ol of steroid -16- alkene (androstene sterol), is initially considered related with underarm odor, but the later contribution found to sense organ and analysis is very
Small (Prokop-Prigge, Greene et al., J Chem Ecol, 2016,33-39).Armpit apocrine secretion liquid is being secreted
When itself be odorless, it is mutual in the armpit microbiologic population of skin surface but due to precursor containing underarm odor in apocrine secretion liquid
Under effect, the smell substances such as 3M2H, HMHA and 3M3SH can be generated.The glutamine conjugate of the sordes matter such as 3M2H, HMHA,
Such as: cys-gly- (S) conjugate (Barzantny, the Brune et of 3M2H-Gln, HMHA-Gln and 3M3SH
Al., International Journal of Cosmetic Science, 2012,2-11) (such as Fig. 2), it is considered to be it closes
Precursor (Martin, Saathoff et al., Journal of Investigative of the body odour object of key
Dermatology, 2010, 529-540, Baumann, Bergmann et al., Experimental
Dermatology, 2014, 247–252).There are mainly of two types for the biggish bacterial population of density in armpit, golden yellow Portugal
Grape coccus (Staphylococcus epidermidis) (Leyden, Mcginley et al., Journal of
Investigative Dermatology, 1981,413-416) and with corynebacteria (Corynebacterium xerosis) (Barzantny, Brune et al., International Journal of Cosmetic Science,
2012, 2-11).Having found that has very strong correlation (Prokop- between the biggish corynebacteria of density and strong underarm odor
Prigge, Greene et al., J Chem Ecol, 2016,33-39).Therefore, it can kill or inhibit these bacterial growths
Substance, have inhibit underarm odor effect.
Studies have shown that the secretion of body odour object precursor is related with the ABCC11 gene of people, the polarization in the apocrine sweat gland of people
In cell, the transport protein matter MRP8 of this gene expression one body odour precursors, without in the crowd of underarm odor, this base
It (is G180R) on protein because 538G > A mutation has occurred.It can be detected in sweat gland in the patient's armpit for having underarm odor
The gene phenotype of ABCC11 is the protein expression of 538GG and 538GA.And it is examined in people's armpit sweat gland that genotype is AA
The expression (Toyoda, Takada et al., Int J Mol Sci, 2017) for not detecting ABCC11 is because of G180R
Mutation compromises N- glycosylation of the MRP8 on two residues of Asn838 and Asn844 in extracellular loop, reduces albumen
The stability of matter, to become easy degradation (Saito, Osumi et al., Aaps Journal, 2009,581).
The MRP8 albumen of ABCC11 coding plays an important role in the excretory function of armpit top gland.Heterozygote (GA) and homozygote
(GG) a physical efficiency secrets out of these body odour precursors in vitro, then, under bacterial action, is metabolized to stink substances.AA is homozygous
The ABCC11 afunction of the armpit top gland of Ziren, the secretion quilt of specific odoring substance amino acid conjugates (body odour object precursor)
It blocks, the secretion for savouring substance and its precursor significantly reduces.These statistics indicate that MRP8 secretion sweat gland in smell and its
Key effect (Martin, Saathoff et al., Journal of Investigative is played in precursor
Dermatology, 2010, 529-540).Possess the prerequisite that allele G is underarm odor expression.Therefore, theoretically, press down
MRP8 activity processed, can reduce the transhipment of body odour precursors；Alpha-glucosidase restrainer can inhibit the N- of protein to glycosylate,
The stability of MRP8 protein can be reduced, to reduce its protein level, can achieve the purpose that inhibit underarm odor.
The technical solution adopted by the present invention to solve the technical problems is: providing a kind of combination of inhibition underarm odor without aluminium
Object, it is characterised in that including following component: 1) antiperspirant inhibits apocrine sweat gland to perspire；2) MRP8 inhibitor inhibits smelly precursors
Transhipment；3) antibacterial agent, can inhibit epidermis staphylococcus aureus (Staphylococcus epidermidis) and rod-like stem
Bacterium (Corynebacterium xerosis) growth；4) auxiliary material.
1) antiperspirant
The antiperspirant is a kind of zinc salt, and this kind of compound contains the polygamy base zinc salt of two or more aglucons, wherein wrapping
Include amino-acid zinc, i.e. glycine zine, alanine zinc, zinc methionine, glutamine zinc, aspartic acid zinc, zinc glutamate, lysine
Zinc, valine zinc, zinc-methionine, isoleucine zinc, phenylalanine zinc, proline zinc, tryptophan zinc, serine zinc, tyrosine
Zinc, Zinc cysteinate, zinc methionine, glutamine zinc, threonine zinc, arginine zinc, histidine zinc, zinc taurine；With it is polynary
Zinc salts of organic acid, i.e. zinc citrate, Tartaric acid zinc, zinc malate, malonic acid zinc, zinc oxalate etc., but it is not limited to these compounds.
The carboxyls containing one or more or amido in each molecule of these compounds, energy and Zn2+Form multiple coordinate bonds.
These zinc salts further include the zinc salt of single aglucon, i.e. zinc gluconate, zinc lactate, ZINC P-PHENOLSULFONATE, zinc sulfate, zinc chloride
With zinc acetate etc., but it is not limited to these compounds.
Zn2+It can inhibit the activity of chloride channel TMEM6A, the formation of primary sweat can be inhibited.Preferably by a kind of or
It is a variety of have compounded containing two or more aglucon zinc salts with the zinc salt of single aglucon of one or more solubilities.Dosage is
0.5%-20%。
2) MRP8 inhibitor
The inhibitor of the MRP8 is a kind of pentacyclic triterpenoid, comprising: enoxolone (Glycyrrhetic acid),
Hawthorn acid (Maslinic acid), oleanolic acid (Oleanolic acid), ursolic acid (Ursolic Acid), Corosolic acid
(Corosolic acid) and asiatic acid (Asiatic acid) and its salt and its derivative.This kind of compound can directly be made
For MRP8 protein, in conjunction with MRP8, inhibits its activity, in formula, can be one such or several combinations,
Its dosage accounts for the 0.01%-5% of total weight.
The inhibitor of the MRP8 is also possible to a kind of alpha-glucosidase restrainer, may include: 1- deoxidation open country buttocks
Mycin and its derivative, such as: 1-DNJ, Beagle spy, Miglitol, and containing the natural of 1-DNJ
Extract, such as: mulberry-leaf extract, this substance inhibit the N- of MRP8 to glycosylate, reduce by inhibiting alpha-glucosidase
MRP8 stability achievees the purpose that inhibit body odour precursors transhipment, dosage accounts for total weight to reduce MRP8 level
0-5%.
Zn2+The activity that can inhibit alpha-glucosidase, polygamy base zinc salt, list containing above-mentioned two or more than two aglucons
The zinc salt and its compound of aglucon are also the inhibitor of MRP8 simultaneously, can reduce MRP8 level, before having inhibition body odour substance
The effect of body transhipment.
3) antibacterial agent
The antibacterial agent is pentacyclic triterpenoid, comprising: enoxolone (Glycyrrhetic acid), hawthorn acid
(Maslinic acid), oleanolic acid (Oleanolic acid), ursolic acid (Ursolic Acid), Corosolic acid
(Corosolic acid) and asiatic acid (Asiatic acid) and its derivative etc..
The antibacterial agent can be a kind of antibacterial enhancing agent, i.e. zinc salt, contain the more of above-mentioned two or more than two aglucons
Aglucon zinc salt, Dan Peiji zinc salt and its compound while also a kind of antibacterial enhancing agent.
4) auxiliary material
The auxiliary material can be surfactant, cosurfactant, grease, conditioner, preservative, one in acidity regulator
Kind or several compoundings.
Surfactant: the surfactant is a kind of nonionic surfactant, such as: fatty alcohol (8-18 carbon)
Polyoxyethylene ether (12-20) is (such as: steareth-20, isosteareth-12, isoceteth-20, ceteareth-20
Deng)；Polyoxyethylene ether (12-25) fatty acid (8-18 carbon) ester is (such as: polyethylene glycol (23) isostearate, polyethylene glycol
(14) oleate, CO40)；(such as: polyethylene glycol (20) lauric acid is sweet for polyethylene glycol (6-23) fatty acid (8-18 carbon) glyceride
Grease, polyethylene glycol (20) olein etc.)；Polyethylene glycol sorbitan mono fatty acid (8-18 carbon) ester (TW-
20, TW-80 etc.)；Fatty acid monosaccharide or polysaccharide esters；Or amphoteric surfactant, such as: lecithin；Anionic surfactant:
Such as: lauryl sodium sulfate；It can be one of or several compoundings.
Cosurfactant: it can be short chain alcohol (C2-C6) such as: ethyl alcohol, propyl alcohol, butanol, 1- hexanol etc.；Polyalcohol is such as:
Propylene glycol, 1,2- butanediol, 1,2- pentanediol, 1,2- hexylene glycol, 1,2- ethohexadiol, glycerine, 1,3- butanol etc.；Short chain acids
Such as: propionic acid, butyric acid, oleic acid；Polyethylene glycols are such as: diethylene glycol ether (carbitol), polyethylene glycol 400 (PEG400), formamide,
Butyl lactate etc.；Amino acids, such as: lysine.Antibacterial agent Spectrastat PHL, which also has, good helps surface-active
Agent effect can be one of or several compoundings.
Grease: the grease can be the esters of short chain, such as: isopropyl myristate, isopropyl palmitate, carbonic acid two
Monooctyl ester, caprylic/capric triglyceride, triethylglycerides, tributyrin, tricaprylin, Capmul PG-8, the third two
Two Off-Shoot-O of alcohol, hexanedioic acid diisopropyl ester, hexanedioic acid dibutyl ester, isopropyl palmitate, ethyl oleate, n butyl oleate, acetyl
Change monoglyceride, ethyl acetate, ethyl butyrate, ethyl caprilate, injection stage soybean oil etc..But it is some to have certain hydrophilic oil
Ester, such as: monoglyceride (glyceryl monolaurate, single grease glyceride, single iso stearate ester, monomyristyl glycerate etc., list
Glycerol caprylate), lactate (such as: lauryl alcohol lactate, myristyl alcohol lactate, C12-13 alcohol lactate, isooctadecanol cream
Acid esters etc.) etc., it can be one of or how compound.
Conditioner: glycerol, propylene glycol, volatile silicone oils, vitamin E etc., antibacterial agent Spectrastat PHL be can be
Also there is opsonic action.
Preservative: can be that some irritations are small, mild preservative, such as: 1,2- hexylene glycol, Spectrastat PHL
Deng.
Acidity regulator, penetration-assisting agent and antioxidant: triethanolamine can be selected in acidity regulator;Azone may be selected in penetration-assisting agent；
Antioxidant selects VE.
The beneficial effects of the present invention are: 1) mechanism is clear, and definite ingredients, 2) aluminium is free of, the crow support without releasable formaldehyde
Safety is used for a long time in product；3) rapid-action, effect is lasting.
Detailed description of the invention
The invention will be further described with reference to the accompanying drawing.
Fig. 1 is the compound chemical structure figure that can be used to inhibit underarm odor.A is pentacyclic triterpenoid.B is that 1- deoxidation is wild
Buttocks mycin (1-DNJ) and its derivative.
Fig. 2 is the body odour object precursor chemical structure chart in armpit apocrine secretion liquid.
Fig. 3 is the component schematic diagram of the embodiment of the present invention.
Fig. 4 is that pentacyclic triterpenoid inhibits MRP8 to the outlet schematic diagram of methotrexate (MTX).
Fig. 5 is that pentacyclic triterpenoid inhibits MRP8 to the IC of the outlet of methotrexate (MTX)50(μM) schematic diagram.
Fig. 6 is minimum inhibitory concentration (MIC) (μ g/ml) schematic diagram to two kinds of underarm odor Related Bacterias of test sample.
Fig. 7 is that several compounds adjust MRP8 level view in cell.
Fig. 8 is that composition compounds component schematic diagram in each embodiment.
Specific embodiment
Referring to Fig. 3, a kind of composition embodiment of the inhibition underarm odor without aluminium of the present invention is a kind of microemulsion, described group
Part composition includes the three parts mixing of basic microemulsion, active constituent and other auxiliary agents, accounts for component in total weight are as follows:
Basic microemulsion: lauryl alcohol lactate (LA-20) 1%-10%, PEG40 castor oil (CO40) 0.5%-10%, glycerine 1%-
20%, dehydrated alcohol 1%-30%, water 30%-80%；Basic microemulsion is transparent, can infinite dilution, and can be according to the molten of contained active matter
Xie Xing selects LA-20 to compound with other greases, such as: LA-20 and ethyl oleate, LA-20 and carbonic diester；
Active constituent: pentacyclic triterpenoid monomer or monomer composition 0.01%-5%, soluble single aglucon or polygamy base zinc
Salt or combinations thereof object 0.5%-10%, 1- dechlorination nojirimycin or derivatives thereof 0-5%.
Other auxiliary agents: lauryl sodium sulfate (K12) 0-3.0%, fatty acid cane sugar ester (SE) 0-3.0%, Spectrastat
PHL 0.1%-4%, azone 0.1%-3%, VE 0-1%, lysine 0.5%-4%, triethanolamine 0.5%-5%, water add to 100%.These
Auxiliary agent can enhance the loading capacity of pentacyclic triterpenoid, improve the dissolubility of polygamy base zinc salt.
The present embodiment is that load active constituent and other auxiliary agents are made on the basis of basic micro emulsion formula of liquid.
Experiment 1: the inhibiting effect that pentacyclic triterpenoid transports MRP8 outlet
In order to measure pentacyclic triterpenoid to the inhibiting effect of MRP8, the cell of MRP8 overexpression is first prepared.It clones first
ABCC11 gene, bibliography (Leier, Jedlitschky et al., Journal of Biological
Chemistry,1994, 27807-27810, Bera, Lee et al., Molecular Medicine, 2001, 509-
516) method, using 5 '-CCT AGT ACT GAT CAC CTGCGC ATC GCT-3 ' and 5 '-AGC GAT GCG CAG
Two primers of GTG ATC ACT AGG-3 ' carry out RACE PCR, and the PCR product of 4.1 kb is cloned into pcDNA3.1 and is carried
Body, obtain plasmid pcDNA3.1 ABCC11, then transfect LLC-PK1 cell, G418 obtains the LLC-PK1- for being overexpressed MRP8 by screening
ABCC11 stable cell line.Pentacyclic triterpenoid to MRP8 outlet inhibiting effect, using LC-MS/MS (Tun-Yhong,
Chinpaisal et al., Antimicrobial Agents & Chemotherapy, 2017, AAC.01725-
01716) method.Firstly, the stable cell line of MRP8 will be expressed with 3 × 105It is a to be inoculated in 12 orifice plates, wherein being cultivated containing M199
Base, 3% heat-inactivated fetal calf serum, 100 μ g/ml are dual anti-and the puromycin hydrochloride of 2 μ g/ml.Cell is in 37 DEG C, 5
The CO of %224 h are cultivated in incubator, the sample being dissolved in DMSO is diluted with culture medium, and then cell is with final concentration of 10 μM
Pentacyclic triterpenoid in 37 DEG C, 5 % CO2 Be incubated for 1 h, add 160 μM of methotrexate (MTX)s (Methotrexate,
MTX), in 37 DEG C, 5 % CO2Shaking table is incubated for 1 h, is washed cell 3 times with the PBS that ice was educated, removes extracellular drug,
Cell is counted, then, floats cell again with the methanol that 100 μ l 70 % (v/v) ice was educated, -20 DEG C of overnight incubations add
Enter 5 μ l(chloramphenicol of inner mark solution, 1.6 μ g/ml), 10,000g 15 min of centrifugation remove cell fragment, using LC-MS/MS
Measure the content of wherein methotrexate (MTX).Liquid chromatogram separates the mobile phase used are as follows: acetonitrile: 1 mM ammonium formate (contains 0.1 % first
Acid) be 18:82(v/v), flow velocity is 0.4 ml/min, using analytical column (C18 Zorbax Eclipse XDB, Agilent
, U.S.A.), 35 DEG C of column temperature.
Experiments have shown that (referring to fig. 4), in the LLC-PK1 cell of expression MRP8, when there is no pentacyclic triterpenoid to deposit
When, methotrexate (MTX) is because by MRP8 outlet, the content in cell is very low.10 μM enoxolone (Glycyrrhetic acid,
GA), hawthorn sour (Maslinic acid, MA), oleanolic acid (Oleanolic acid, OA), ursolic acid (Ursolic Acid,
UA), Corosolic acid (Corosolic acid, CA) and asiatic acid (Asiatic acid, AA) can significantly inhibit
Transhipment of the MRP8 to methotrexate (MTX) improves intake of the cell to methotrexate (MTX), therefore these pentacyclic triterpenoids can inhibit
The transhipment of MRP8 (referring to Fig. 5).
Experiment 2: antibacterial activity of the pentacyclic triterpenoid to epidermis staphylococcus aureus and corynebacteria
Pentacyclic triterpenoid has the antibacterial activity of staphylococcus aureus and corynebacteria, experiment with bacterial species: epidermis
Staphylococcus aureus (Staphylococcus epidermidis) and corynebacteria (Corynebacterium xerosis), it is the main relevant bacteria species of underarm odor.Test sample are as follows: enoxolone (Glycyrrhetic acid, GA), hawthorn acid
(Maslinic acid, MA), oleanolic acid (Oleanolic acid, OA), ursolic acid (Ursolic Acid, UA), koroso
Acid (Corosolic acid, CA) and asiatic acid (Asiatic acid, AA) etc. are the positive with Kanamycin Sulfate
Control, using methanol as negative control.Measuring method bibliography method (Rahman M.& Gray A.,
Phytochemistry, 2005,66 :1601-1606).Sample to be tested, Kanamycin Sulfate are dissolved in methanol respectively
(MeOH) in, the solution for becoming l mg/ml is prepared.The resazurin indicator of 100 μ g/ml is added to 96 porocyte culture plates
The 12nd column hole in, the resazurin solution and 5 ml of 7. 5 ml100 μ g/ml are containing bacterium (106 cfu/ml, OD=O.07)
Culture solution mix, be then respectively adding to 1-11 column in, be added in each culture hole the above-mentioned resazurin of 100 μ l and bacterium training
The mixture of nutrient solution.The sample being dissolved in DMSO, is diluted with culture medium, then is added into first hole of each column in culture plate
100 μ l concentration are the test sample of l mg/ml, mix, therefrom draw 100 μ l solution and get in second hole, according to this class
It pushes away, until the tenth hole, finally removes 100 μ l.The concentration of test sample changes are as follows: 500 μ g/ml, 250 μ g/ml, 125 μ
G/ml, 62.5 μ g/ml, 31.2 μ g/ml, 15.6 μ g/ml, 7.8 μ g/ml, 3.9 μ g/ml, 1.9 μ g/ml and 0.9 μ g/ml；Then
Culture plate is placed on 370It is cultivated in the incubator of C 5-6 hours, not becoming pink from blue indicates antibacterial activity.When the 11st
When column culture solution becomes pink from blue, it is test sample that the last one, which does not become sample concentration in the hole of pink from blue,
Minimum inhibitory concentration (MIC).The result shows that (Fig. 6), these pentacyclic triterpenoids are to staphylococcus aureus and rod-like stem
Bacterium has good antibacterial activity.
Test 3:1- 1-Deoxynojirimycin (1-DNJ) and Zn2+ To the inhibiting effect of MRP8
1-DNJ is alpha-glucosidase restrainer.We have detected 1-DNJ, mulberry-leaf extract and
Zn2+ Inhibitor effect to the stability of MRP8.MDCKII cell in DMEM (contain calf serum 10%, it is dual anti-1%)
In 37 DEG C of 5% CO2Incubator in cultivate.By plasmid pcDNA3.1 ABCC11 transfect MDCKII cell, transfect 48 hours
Afterwards, cell is separately added into the 1-DNJ of 4.0 μ g/ml, the mulberry-leaf extract of 400 μ g/ml, 50 μ g/ml glucose
Sour zinc, 10 μ g/ml zinc sulfate, then it is incubated for 24 h.Glycosidase PNGase F is added in lytic cell, in 37 DEG C of 10 min of processing,
Then protein Western Blot analysis is carried out.
As a result such as Fig. 7.This is it is demonstrated experimentally that the adjustable MRP8 of 1-DNJ is horizontal, this is because 1- deoxidation
Nojirimycin is alpha-glucosidase restrainer, can inhibit N- glycosylation of the MRP8 on 838 and 844.Mulberry
Contain the 1-DNJ of 1 %-5 % in leaf extract.The N substituent of 1-DNJ, such as: Beagle spy, rice
Lattice column alcohol and the glycosylated inhibitor of N-, should be able to reduce the level of MRP8.
50 μ g/ml zinc gluconates and 10 μ g/ml zinc sulfate can also reduce MRP8 level, this may be with Zn2+ Energy
Inhibit alpha-glucosidase related, to reduce the N- level of glycosylation of MRP8.
Since these substances can inhibit the N- of MRP8 to glycosylate, to reduce the stability of MRP8, its albumen is reduced
Matter is horizontal, therefore, 1-DNJ and Zn2+ It can inhibit the transhipment of sordes matter.
Test 4:Zn2+ Inhibit the chloride ion outflow of TMEM16A induction
Inhibit the Cl in sweat gland cells- Outflow can inhibit the formation of primary sweat, achieve the purpose that inhibit to perspire.Mankind's sweat
Gland cell system NCL-SG3 (10 % containing calf serum, dual anti-1 %) in William's E culture medium, cell density is
20,000 cells/well, in 96 orifice plates of black, in 37 DEG C of 5 % CO2 Incubator in cultivate.By yellow fluorescence
The consolidation constitution grain pCDNA3.1-YFP (H148Q/I152L/F46L) of albumen is transferred in cell.Second day, 200 μ of every hole
The PBS of l is washed 3 times, every hole addition 50 μ l PBS, 0.5 μ l untested compound DMSO solution, after 10 min,
Intracellular background fluorescence (intensifying 500 ± 10 nm of light, emit 535 ± 15 nm of light) is measured on FLIPR Tetr, background is glimmering
Light makees positive control (inhibiting rate is 0 %) and then 50 μ l is added and (are used for containing 140 mM NaI and 200 μM of ATP solution
Measure TMEM16A, Ca2+Activation) after 6 min, measure the fluorescence in each hole.When the TMEM16A in cell is activated by ATP
When, extracellular I- ion enters cell, Cl- Cell is flowed out, the yellow fluorescence of YFP is by I in cell- It is quenched, fluorescence is strong
Degree reduce, using in the presence of ATP without the measured value under the conditions of untested compound as negative control (inhibiting rate is 100 %).Change
Close the inhibiting rate of object are as follows: value-positive control value of 1-(untested compound)/100 % of (negative control value-positive control value) X,
And calculate IC50.Zinc gluconate inhibits Cl- The IC of outflow50Value be 80.85 ± 0.28 μM, zinc sulfate be 10.85 ±
0.28 μM, therefore, contain Zn2+ Compound has antiperspirant effect.
The present invention can be a kind of creme or a kind of tincture or a kind of spray or a kind of Roll on agent.
Production method
According to the formula (Fig. 8) of the embodiment, produced using the following method.
Embodiment 1:
It mixes according to the ratio, dress is packed into spray bottle, is spray.This agent side is transparent, stablizes.
Embodiment 2:
According to the ratio, by enoxolone (GA), 1-DNJ (1-DNJ), cetearyl alcohol alcohol ether -6 (A6), cetearyl alcohol
Alcohol/cetearyl alcohol alcohol ether -25 (A25), fatty acid cane sugar ester (SE), lauryl alcohol lactate (LA20), PGCC,
Spectrastat PHL, azone, vitamin E (VE), triethanolamine, glycerol, dehydrated alcohol are mixed to Quan Rong, by lysine plus
Enter into solvable single aglucon zinc solution of 10 % and dissolve, is then added in the mixed liquor of front, stirs half an hour, obtain transparent
Microemulsion, be fitted into spray bottle, be spray.
Embodiment 3:
According to the ratio, by enoxolone (GA), 1-DNJ (1-DNJ), CO40, lauryl alcohol lactate (LA20),
Spectrastat PHL, azone, vitamin E (VE), triethanolamine, glycerol, dehydrated alcohol are mixed to Quan Rong, by lysine plus
Enter into solvable single aglucon zinc solution of 10 % and dissolve, is then added in the mixed liquor of front, stirs half an hour, obtain transparent
Microemulsion, be fitted into spray bottle, be spray.
Embodiment 4:
According to the ratio, enoxolone (GA), CO40, lauryl alcohol lactate (LA20), Spectrastat PHL, azone, dimension are given birth to
Plain E (VE), triethanolamine, glycerol, dehydrated alcohol are mixed to Quan Rong, add fatty acid cane sugar ester (SE), lysine, solvable
It is dissolved in single aglucon zinc salt and polygamy base zinc solution, adds water to 100 %, stir half an hour, obtain transparent lotion, be packed into spray
Bottle is spray.
Claims (6)
1. a kind of composition of the inhibition underarm odor without aluminium, it is characterised in that including being free of aluminium component: 1) antiperspirant as follows, inhibit
Apocrine sweat gland perspires；2) MRP8 inhibitor inhibits the transhipment of smelly precursors；3) antibacterial agent inhibits epidermis staphylococcus aureus
And corynebacteria；4) auxiliary material.
2. the composition of the inhibition underarm odor according to claim 1 without aluminium, it is characterised in that: the antiperspirant is polygamy
Base zinc salt and single aglucon zinc salt, including amino-acid zinc, alanine zinc, zinc methionine, glutamine zinc, aspartic acid zinc,
Zinc glutamate, lysine-zn, valine zinc, zinc-methionine, isoleucine zinc, phenylalanine zinc, proline zinc, tryptophan zinc,
Serine zinc, tyrosine zinc, Zinc cysteinate, zinc methionine, glutamine zinc, threonine zinc, arginine zinc, histidine zinc,
Zinc taurine；With multicomponent organic acid zinc salt, i.e. zinc citrate, Tartaric acid zinc, zinc malate, malonic acid zinc, zinc oxalate；Single aglucon
Zinc salt can be one such including zinc gluconate, zinc lactate, ZINC P-PHENOLSULFONATE, zinc sulfate, zinc chloride and zinc acetate
The compounding of a variety of compoundings or polygamy base zinc salt and single aglucon zinc salt, dosage are 0.5 %-20 % of overall weight.
3. the composition of the inhibition underarm odor according to claim 1 without aluminium, it is characterised in that: the inhibition of the MRP8
Agent is pentacyclic triterpenoid and its derivative, including enoxolone, hawthorn acid, oleanolic acid, ursolic acid, Corosolic acid or
Asiatic acid and its salt and derivative, can be one such or several combinations, and dosage accounts for 0.01 %-5 of total weight
%。
4. the composition of the inhibition underarm odor according to claim 1 without aluminium, it is characterised in that: the suppression of the MRP8
Preparation is alpha-glucosidase restrainer, 1-DNJ and its derivative, including 1-DNJ, Beagle
Special, Miglitol, can be one such or several combinations, dosage accounts for the 0-5 % of total weight.
5. the composition of the inhibition underarm odor according to claim 1 without aluminium, it is characterised in that: the antibacterial agent is five rings
Triterpene compound and its derivative, including careless hypo acid, hawthorn acid, oleanolic acid, ursolic acid, Corosolic acid or asiatic acid,
And its salt and derivative.
6. the composition of the inhibition underarm odor according to claim 1 without aluminium, it is characterised in that: the component be include base
Plinth microemulsion, active constituent and the mixing of other auxiliary agent three parts, account for component in total weight and are respectively as follows:
Basic microemulsion: 1 %-10 % of lauryl alcohol lactate, 0.5 %-10 % of PEG40 castor oil, 1 %-20 % of glycerine, anhydrous
1 %-30 % of ethyl alcohol, 30 %-80 % of water；
Active constituent: 0.01 %-5 % of pentacyclic triterpenoid monomer or monomer composition, soluble single aglucon or polygamy base
0.5 %-10 % of zinc salt or composition, 1- dechlorination nojirimycin or derivatives thereof 0-5 %；
Other auxiliary agents: lauryl sodium sulfate 0-3.0 %, fatty acid cane sugar ester 0-3.0 %, 0.1 %- of Spectrastat PHL
4 %, 0.1 %-3 % of azone, VE 0-1 %, 0.5 %-4 % of lysine, 0.5 %-5 % of triethanolamine, water add to 100 %.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910448380.8A CN110124042A (en) | 2019-05-28 | 2019-05-28 | The composition of inhibition underarm odor without aluminium |
| CN202311204331.2A CN116999557A (en) | 2019-05-28 | 2019-05-28 | Aluminum-free composition for inhibiting bromhidrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910448380.8A CN110124042A (en) | 2019-05-28 | 2019-05-28 | The composition of inhibition underarm odor without aluminium |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311204331.2A Division CN116999557A (en) | 2019-05-28 | 2019-05-28 | Aluminum-free composition for inhibiting bromhidrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110124042A true CN110124042A (en) | 2019-08-16 |
Family
ID=67582171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910448380.8A Pending CN110124042A (en) | 2019-05-28 | 2019-05-28 | The composition of inhibition underarm odor without aluminium |
| CN202311204331.2A Pending CN116999557A (en) | 2019-05-28 | 2019-05-28 | Aluminum-free composition for inhibiting bromhidrosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311204331.2A Pending CN116999557A (en) | 2019-05-28 | 2019-05-28 | Aluminum-free composition for inhibiting bromhidrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN110124042A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022122598A1 (en) * | 2020-12-07 | 2022-06-16 | Unilever Ip Holdings B.V. | Antiperspirant compositions |
| CN117717492A (en) * | 2023-12-19 | 2024-03-19 | 中山自然说生物科技有限公司 | Biological agent for repairing armpit microecology and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101336966A (en) * | 2008-08-14 | 2009-01-07 | 重庆灵方生物技术有限公司 | Osmidrosis dispelling liniment containing natural essential oil of Zingiber corallinum Hance |
| CN102151287A (en) * | 2010-12-14 | 2011-08-17 | 徐玉仙 | Bromhidrosis treating powder |
| CN104622703A (en) * | 2013-11-14 | 2015-05-20 | 无锡丝源化妆品有限公司 | Deodorant powder and preparation method thereof |
| WO2018023126A1 (en) * | 2016-07-29 | 2018-02-01 | Kaspar Roger L | Methods of treating osmidrosis |
-
2019
- 2019-05-28 CN CN201910448380.8A patent/CN110124042A/en active Pending
- 2019-05-28 CN CN202311204331.2A patent/CN116999557A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101336966A (en) * | 2008-08-14 | 2009-01-07 | 重庆灵方生物技术有限公司 | Osmidrosis dispelling liniment containing natural essential oil of Zingiber corallinum Hance |
| CN102151287A (en) * | 2010-12-14 | 2011-08-17 | 徐玉仙 | Bromhidrosis treating powder |
| CN104622703A (en) * | 2013-11-14 | 2015-05-20 | 无锡丝源化妆品有限公司 | Deodorant powder and preparation method thereof |
| WO2018023126A1 (en) * | 2016-07-29 | 2018-02-01 | Kaspar Roger L | Methods of treating osmidrosis |
Non-Patent Citations (7)
| Title |
|---|
| ANNETTE MARTIN ET AL.: "A Functional ABCC11 Allele Is Essential in the Biochemical Formation of Human Axillary Odor", 《JOURNAL OF INVESTIGATIVE DERMATOLOGY》 * |
| YU TOYODA ET AL.: "Regulation of the Axillary Osmidrosis-Associated ABCC11 Protein Stability by N-Linked Glycosylation: Effect of Glucose Condition", 《PLOS ONE》 * |
| 孙杨等: "ABCC11基因单核苷酸多态性与中国汉族人群腋臭发病的相关性研究", 《中南大学学报（医学版）》 * |
| 宋有涛等: "《分子伴侣与蛋白质错误折叠》", 31 March 2012, 辽宁科学技术出版社 * |
| 杨建峰等: "《老偏方》", 30 November 2014, 江西科学技术出版社 * |
| 陈正伦: "《兽医中药药理学》", 31 May 1995, 中国农业出版社 * |
| 黄荣: "《化妆品制备基础》", 31 May 2015, 四川大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022122598A1 (en) * | 2020-12-07 | 2022-06-16 | Unilever Ip Holdings B.V. | Antiperspirant compositions |
| CN117717492A (en) * | 2023-12-19 | 2024-03-19 | 中山自然说生物科技有限公司 | Biological agent for repairing armpit microecology and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116999557A (en) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9555057B2 (en) | Compositions and methods for reducing cutaneous microbiome malodor | |
| CN110124042A (en) | The composition of inhibition underarm odor without aluminium | |
| US20160317419A1 (en) | Method of improving skin health and compositions therefor | |
| US20190343835A1 (en) | Hair loss treatment composition and method | |
| WO2020132930A1 (en) | Anti-dandruff anti-itch shampoo composition containing multiple-component zinc | |
| KR20180054647A (en) | Skin lightening composition | |
| CN110177463A (en) | 2- hydroxy benzylamine is treating and preventing the application in pulmonary hypertension | |
| JP6474963B2 (en) | Cleaning composition | |
| JP2020164548A (en) | Composition containing meso-2,3-butanediol | |
| KR20160046639A (en) | Composition for external application to the skin containing meso-2,3-butanediol as a preservative | |
| JPH11286423A (en) | Composition for suppressing body odor | |
| US9125928B2 (en) | Agent for suppressing the formation of abnormal skin cells caused by exposure to light | |
| EP3536316A1 (en) | Acne strain-selective antibacterial agent | |
| US10596092B2 (en) | Deodorant composition and a method for preparing thereof | |
| JP2018517665A (en) | Compositions and methods for reducing or preventing or reversing skin pigmentation in mammalian subjects | |
| JP2019081763A (en) | Cleaning composition | |
| KR101588841B1 (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Ocimene as Active Ingredients | |
| Haustein et al. | Growth inhibition of coryneform bacteria by a mixture of three natural products-Farnesol, glyceryl monolaurate, and phenoxyethanol: HGQ | |
| JP5025535B2 (en) | Antibacterial agent composition and deodorant composition | |
| Heinke et al. | Involvement of calmodulin and protein kinase C in the regulation of K+ transport by carbachol across the rat distal colon | |
| JP2007197349A (en) | Transdermal absorption type pharmaceutical | |
| Shakhov et al. | Antioxidant status in albino rats vaccinated against salmonellosis under chronic action of T-2 toxin and its correction by aminoseleton | |
| US20220087968A1 (en) | Composition for promoting the skin microbiome | |
| JP5483820B2 (en) | Antibacterial composition and deodorant | |
| JP5710189B2 (en) | Skin lotion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |